Raymond James analyst Daryl Swetlishoff downgrades Conifex Timber (TSX:CFF) from Outperform to Market Perform and lowers the price target from C$2 to C$1.95.
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson’s Data
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.